STAT6 and neoplasm: Furthermore, additional mutations in PTCH1 (subclonal), PDGFRB, and the NAB2-STAT6 fusion were confirmed as a somatic event in tumor tissue, none of which have reported therapeutic options with clinical benefit in patient’s tumor type.